The global whole genome sequencing market is projected to reach $7.17 billion by 2031 at a CAGR of 15.2% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the spirometers market is driven by the declining costs of sequencing, the increasing prevalence of cancer & genetic disorders, the growing utilization of whole genome sequencing in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for whole genome sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high costs of whole genome sequencing consumables, the low chances of identifying positive, actionable mutations for precision medicine, and the ethical & legal issues related to whole genome sequencing-based diagnosis restrain the growth of this market.
Furthermore, increasing applications of whole genome sequencing, government support for large-scale genomic sequencing projects, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, the uncertainties in the regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the lack of sequencing professionals in developing countries, and the high capital investments required for NGS setups pose a major challenge to market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China).
Among all the offerings studied in this report, the consumables segment is expected to account for the largest share of over 70.1% of the whole genome sequencing market. This segment’s large market share can be attributed to the recurring use of consumables, continuous advancements in reagents and target enrichment protocols and associated consumables, and the increasing applications of whole genome sequencing in clinical settings.
Among all the sequencing types studied in this report, in 2024, the whole genome sequencing segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to the large whole genome sequencing provides high resolution and base-by-base view of the genome and helps in sequencing large genome for providing population-level studies.
Among all the technologies studied in this report, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to the widespread adoption of sequencing by synthesis technology, which offers high accuracy and supports both paired-end and single-read libraries, enabling high-resolution genome sequencing.
Among all the applications studied in this report, in 2024, the research applications segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share is attributed to the increasing use of whole genome sequencing to identify novel drug targets, the rising demand for gene-based medicines, and growing investments in drug research and development activities.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to increased R&D spending by pharmaceutical and biotechnology firms, along with the rising incidence of genetic diseases, which is fueling the adoption of whole genome sequencing in these industries.
An in-depth analysis of the geographical scenario of the global whole genome sequencing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 52.1% of the whole genome sequencing market. In the region in 2024, the U.S. is expected to account for the largest share of the whole genome sequencing market in North America. North America’s significant market share can be attributed to factors such as high awareness of whole genome sequencing, favorable government initiatives supporting genomics research, increasing applications of NGS-based research, decreasing sequencing costs, a high prevalence of cancer, and a supportive reimbursement scenario.
Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the spirometers market is driven by the declining costs of sequencing, the increasing prevalence of cancer & genetic disorders, the growing utilization of whole genome sequencing in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for whole genome sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high costs of whole genome sequencing consumables, the low chances of identifying positive, actionable mutations for precision medicine, and the ethical & legal issues related to whole genome sequencing-based diagnosis restrain the growth of this market.
Furthermore, increasing applications of whole genome sequencing, government support for large-scale genomic sequencing projects, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, the uncertainties in the regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the lack of sequencing professionals in developing countries, and the high capital investments required for NGS setups pose a major challenge to market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China).
Among all the offerings studied in this report, the consumables segment is expected to account for the largest share of over 70.1% of the whole genome sequencing market. This segment’s large market share can be attributed to the recurring use of consumables, continuous advancements in reagents and target enrichment protocols and associated consumables, and the increasing applications of whole genome sequencing in clinical settings.
Among all the sequencing types studied in this report, in 2024, the whole genome sequencing segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to the large whole genome sequencing provides high resolution and base-by-base view of the genome and helps in sequencing large genome for providing population-level studies.
Among all the technologies studied in this report, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to the widespread adoption of sequencing by synthesis technology, which offers high accuracy and supports both paired-end and single-read libraries, enabling high-resolution genome sequencing.
Among all the applications studied in this report, in 2024, the research applications segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share is attributed to the increasing use of whole genome sequencing to identify novel drug targets, the rising demand for gene-based medicines, and growing investments in drug research and development activities.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to increased R&D spending by pharmaceutical and biotechnology firms, along with the rising incidence of genetic diseases, which is fueling the adoption of whole genome sequencing in these industries.
An in-depth analysis of the geographical scenario of the global whole genome sequencing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 52.1% of the whole genome sequencing market. In the region in 2024, the U.S. is expected to account for the largest share of the whole genome sequencing market in North America. North America’s significant market share can be attributed to factors such as high awareness of whole genome sequencing, favorable government initiatives supporting genomics research, increasing applications of NGS-based research, decreasing sequencing costs, a high prevalence of cancer, and a supportive reimbursement scenario.
Scope of the Report:
Whole Genome Sequencing Market Assessment - by Offering
- Consumables
- Sample Preparation Kits & Reagents
- Nucleic Acid Extraction & Amplification
- Library Preparation & Target Enrichment
- Quality Control
- Other Consumables
- Instruments
- Software
- Services
Whole Genome Sequencing Market Assessment - by Sequencing Type
- Large Whole-Genome Sequencing
- Small Whole-Genome Sequencing
- Human Whole-Genome Sequencing
- Other Whole-Genome Sequencing Types
Whole Genome Sequencing Market Assessment - by Technology
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- DNA Nanoball Sequencing
- Single-molecule Real-time Sequencing
- Other NGS Technologies
Whole Genome Sequencing Market Assessment - by Application
- Research and Other Applications
- Drug Discovery
- Agriculture and Animal Research
- Other Applications
- Clinical Applications
- Reproductive Health
- Oncology
- Infectious Diseases
- Other Clinical Applications
Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.
Whole Genome Sequencing Market Assessment - by End User
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic Laboratories
- Academic Institutes & Research Centers
- Other End Users
Whole Genome Sequencing Market Assessment - by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific (RoAPAC)
- Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATM)
- Middle East & Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Whole Genome Sequencing Market Assessment - by Offering
6. Whole Genome Sequencing Market Assessment - by Sequencing Type
7. Whole Genome Sequencing Market Assessment - by Application
8. Whole Genome Sequencing Market Assessment - by Technology
9. Whole Genome Sequencing Market Assessment - by End User
10. Whole Genome Sequencing Market Assessment - by Geography
11. Competition Analysis
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Illumina Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S)
- QIAGEN N.V. (Netherlands)
- F. Hoffmann-La Roche Ltd (Switzerland)
- PerkinElmer Inc. (U.S) Agilent Technologies Inc. (U.S)
- Pacific Biosciences of California Inc. (U.S)
- Danaher Corporation (U.S)
- Bio-Rad Laboratories Inc. (U.S.)
- Oxford Nanopore Technologies Plc. (U.K)
- MGI Tech Co.
- Ltd. (China)
- Beijing Genomics Institute (BGI) (China)
